Gifts for the issues faced by the construction of an innovative company developing space with new intellectual property in terms of the venture capitalist. Beth Seidenberg, a partner at venture capital firm Kleiner Perkins Caufield & Byers (KPCB), helped draw Izumi Bio, a company with ambitious prospects, which it believed had the potential to become "the" ultimate stem cell company. IZUMI sought to bring under the banners of key intellectual property (IP) to the nascent field of stem cell technology. Thus, Izumi to acquire the rights to several groundbreaking scientific developments that have recently taken place in laboratories around the world. Seidenberg, you must decide whether to make the next major tranche of investment. Charged with the completion of its decision in less than 24 hours, Seidenberg weighed the pros and cons of the next round of funding. Is it really possible to bring together such a wide range of IP under one roof? Was an international mix of IP will be too difficult to manage? Whether it was too early for stem cell technologies for successful business? "Hide
by Robert F. Higgins, Jacob Brodeur-Fingert, Elliot Sherman, Sidhartha Palani Source: HBS Premier Case Collection 39 pages. Publication Date: 08 January 2009. Prod. #: 809105-HCB-ENG
Related Case Solutions & Analyses:
Porto Adriatico
Telecommunications Regulation and Coordinated Competition in Romania
Altoids
Patricia Hughes Mason
International Use of the Myers-Briggs Type Indicator
Standard Costs and Variances
Decisions by Design: Stop Deciding, Start Designing
Knight Riders Digital Venture
Canadian national railway company cultural change
Business Communication
